These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25381425)

  • 1. Understanding the role of rituximab in ANCA GN: regressing toward the mean.
    Pendergraft WF; Falk RJ
    J Am Soc Nephrol; 2015 Apr; 26(4):771-4. PubMed ID: 25381425
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab to treat ANCA-associated vasculitis].
    Guillevin L; Mahr A
    Rev Med Interne; 2011 Oct; 32(10):591-3. PubMed ID: 21872370
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C; Manoharan P; Carter-Monroe N; Geetha D
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Hebert LA; Ardoin S; Shim RL
    N Engl J Med; 2010 Nov; 363(21):2072-3; author reply 2073-4. PubMed ID: 21083399
    [No Abstract]   [Full Text] [Related]  

  • 8. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P; Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Schönermarck U; Rau S; Fischereder M
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083401
    [No Abstract]   [Full Text] [Related]  

  • 10. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Kronbichler A; Jayne DR
    Nephrol Dial Transplant; 2015 Jul; 30(7):1075-81. PubMed ID: 25999374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in AAV: when and how to use it.
    Holle JU; Gross WL
    Nat Rev Rheumatol; 2011 Aug; 7(10):566-7. PubMed ID: 21878889
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
    Moog P; Schulze-Koops H; Thürmel K
    Rheumatology (Oxford); 2015 Feb; 54(2):372-3. PubMed ID: 25205824
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis?
    Tarzi R; Pusey C
    Nat Rev Nephrol; 2013 Nov; 9(11):628-9. PubMed ID: 24080801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on: induction treatment of ANCA-associated vasculitis with a single dose of rituximab: reply.
    Turner-Stokes T; Sandhu E; Pepper RJ; Salama AD; Burns A; Little MA
    Rheumatology (Oxford); 2015 Feb; 54(2):373-4. PubMed ID: 25433044
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasculitis: Rituximab: effective in ANCA-associated vasculitis?
    Schönermarck U; de Groot K
    Nat Rev Nephrol; 2011 Jan; 7(1):6-8. PubMed ID: 21173754
    [No Abstract]   [Full Text] [Related]  

  • 17. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Nossent JC
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083400
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
    Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
    N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of ANCA-associated vasculitis ... 40 years later].
    Arazzi M
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24941484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.